About Neurotrope (OTCMKTS:NTRP)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
Industry, Sector and Symbol:
- Market Cap: $36.71 million
- Outstanding Shares: 7,895,000
- 50 Day Moving Avg: $5.08
- 200 Day Moving Avg: $7.57
- 52 Week Range: $3.40 - $29.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.37
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.47 per share
- Price / Book: 1.88
- EBITDA: ($14,660,000.00)
- Return on Equity: -57.00%
- Return on Assets: -51.84%
- Current Ratio: 3.45%
- Quick Ratio: 3.45%
- Average Volume: 31,628 shs.
- Beta: 2.6
- Short Ratio: 1.72
Frequently Asked Questions for Neurotrope (OTCMKTS:NTRP)
What is Neurotrope's stock symbol?
Neurotrope trades on the OTCMKTS under the ticker symbol "NTRP."
How were Neurotrope's earnings last quarter?
Neurotrope Inc (OTCMKTS:NTRP) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. View Neurotrope's Earnings History.
Where is Neurotrope's stock going? Where will Neurotrope's stock price be in 2017?
1 equities research analysts have issued 12-month target prices for Neurotrope's stock. Their forecasts range from $31.00 to $31.00. On average, they expect Neurotrope's share price to reach $31.00 in the next year. View Analyst Ratings for Neurotrope.
Who are some of Neurotrope's key competitors?
Some companies that are related to Neurotrope include Evolving Systems (EVOL), Determine (DTRM), Scisys Plc (SSY), Top Image Systems (TISA), Sopheon Plc (SPE), Inuvo (INUV), Smith Micro Software (SMSI), Zoo Digital Group plc (ZOO), Vipera Plc (VIP), CounterPath Corporation (CPAH), Accelrys (ACCL), Actuate Corp (BIRT), BMC Software (BMC), Concur Technologies (CNQR), Cvent (CVT), D4t4 Solutions PLC (ISL), eFuture Holding (EFUT) and EnerNOC (ENOC).
Who are Neurotrope's key executives?
Neurotrope's management team includes the folowing people:
- Joshua N. Silverman, Chairman of the Board
- Daniel L Alkon M.D., President, Chief Scientific Officer
- Susanne Wilke Ph.D., Chief Executive Officer, Director
- William S. Singer, Vice Chairman of the Board
- Robert Weinstein, Chief Financial Officer, Executive Vice President
- Paula T. Trzepacz, Executive Vice President and Chief Medical Officer
- Bruce T. Bernstein, Director
- Kenneth J. Gorelick, Director
- Andrew D. Perlman, Director
- Shana Phares, Director
How do I buy Neurotrope stock?
Shares of Neurotrope can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurotrope's stock price today?
MarketBeat Community Rating for Neurotrope (OTCMKTS NTRP)MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Neurotrope stock can currently be purchased for approximately $4.65.
Consensus Ratings for Neurotrope (OTCMKTS:NTRP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$31.00|Consensus Price Target History for Neurotrope (OTCMKTS:NTRP)
Analysts' Ratings History for Neurotrope (OTCMKTS:NTRP)
(Data available from 10/22/2015 forward)
Earnings History for Neurotrope (OTCMKTS:NTRP)Earnings History by Quarter for Neurotrope (OTCMKTS NTRP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Neurotrope (OTCMKTS:NTRP)
Current Year EPS Consensus Estimate: $-1.89 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS
Dividend History for Neurotrope (OTCMKTS:NTRP)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Neurotrope (OTCMKTS:NTRP)
Latest Headlines for Neurotrope (OTCMKTS:NTRP)
Loading headlines, please wait.
Neurotrope (NTRP) Chart for Sunday, October, 22, 2017